Addition of GM-CSF Does Not Improve Response to Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab and Rituximab

Thirty-three previously untreated patients with high risk CLL were treated before meeting standard criteria with alemtuzumab and rituximab. GM-CSF was added to the regimen to determine if it would improve treatment efficacy without increasing toxicity. High risk was defined as at least one of the fo...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Leuk Lymphoma
المؤلفون الرئيسيون: Zent, Clive S., Wu, Wenting, Bowen, Deborah A., Hanson, Curtis A., Pettinger, Adam M., Shanafelt, Tait D., Kay, Neil E., Leis, Jose F., Call, Timothy G.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2012
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4419690/
https://ncbi.nlm.nih.gov/pubmed/22853816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.717276
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة